Suppr超能文献

重新审视罕见病的风险:网络、溢出效应和规模的经济学

Reframing risks in rare diseases: economics of networks, spillovers, and scale.

作者信息

Runge Carlisle Ford, Campbell James, Runge Carlisle P

机构信息

Department of Applied Economics, University of Minnesota, St. Paul, MN, United States.

Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, United States.

出版信息

Front Pharmacol. 2024 Dec 10;15:1516725. doi: 10.3389/fphar.2024.1516725. eCollection 2024.

Abstract

Rare diseases affect over three hundred million individuals globally. Investment in research and development remains incommensurate with the challenges rare diseases pose. Further investment in information sharing platforms to promote common and standardized network technologies for rare disease is needed. Rare disease R&D generates information and assets that spill over in other ways, providing benefits that may not be apparent to investors Analytical and computational methods recently applied at scale are promising. One important way of achieving efficiencies of scale in R&D is clustering rare diseases into groups with similar traits.

摘要

全球有超过3亿人受罕见病影响。对研发的投入与罕见病带来的挑战仍不相称。需要进一步投资于信息共享平台,以推广用于罕见病的通用和标准化网络技术。罕见病研发产生的信息和资产会以其他方式外溢,带来投资者可能并不明显的益处。最近大规模应用的分析和计算方法很有前景。在研发中实现规模效率的一个重要方法是将罕见病聚类为具有相似特征的组。

相似文献

4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
7

本文引用的文献

1
De-risking rare disease acquisitions: a win-win-win for patients, biotech and investors.
Nat Rev Drug Discov. 2024 Jan;23(1):10-11. doi: 10.1038/d41573-023-00190-x.
9
Drug Repurposing for Rare Diseases.药物重用于罕见病。
Trends Pharmacol Sci. 2021 Apr;42(4):255-267. doi: 10.1016/j.tips.2021.01.003. Epub 2021 Feb 6.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验